title: Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).
abstract: OBJECTIVE
  To evaluate the clinical value of detected prostate-specific antigen (PSA) mRNA expression levels in circulating cells in patients with prostate cancer by quantitative real-time polymerase chain reaction (qRT-PCR) and to determine the effect of surgical manipulation on hematogenous dissemination.
  
  
  METHODS
  Blood samples before, during, and after (24 h) surgery were obtained from 34 patients with prostate cancer who underwent radical prostatectomy for detecting PSA mRNA expression levels. PSA mRNA expression levels, PSA levels, and Gleason scores were then compared.
  
  
  RESULTS
  PSA mRNA expression levels were detected in 14 of 34 (41%) patients, and biochemical recurrence of blood PSA was observed in 6 of 34 (17%) patients. Differences of PSA mRNA expression levels in pre-, per-, and postoperative periods were statistically significant (P < 0.001) and differences of PSA mRNA expression levels in pre- and peroperative samples (P < 0.008), pre- and postoperative samples (P < 0.031), and per- and postoperative samples (P < 0.001) were also statistically meaningful. There was significant relationship between the detectable PSA mRNA expression levels in preoperative samples and biochemical recurrence of blood PSA levels. We demonstrated that surgical manipulation had no effect on biochemical recurrence of blood PSA. We also showed that there was significant correlation between high Gleason score and the detectable PSA mRNA expression levels (P < 0.027).
  
  
  CONCLUSIONS
  Our results suggest that highly detectable PSA mRNA expression levels in preoperative samples seem to be a significant predictable factor for prostate cancer recurrence.
authors.affiliation: Department of Urology, Bakirkoy Training and Research Hospital, Istanbul, Turkey. nadirkalfazade@gmail.com
authors.forename: Nadir
authors.initials: N
authors.lastname: Kalfazade
authors.forename: Ahmet M
authors.initials: AM
authors.lastname: Kuskucu
authors.forename: Serdar
authors.initials: S
authors.lastname: Karadag
authors.forename: Selcuk
authors.initials: S
authors.lastname: Sahin
authors.forename: Bekir
authors.initials: B
authors.lastname: Aras
authors.forename: Kenan
authors.initials: K
authors.lastname: Midilli
authors.forename: Gülden
authors.initials: G
authors.lastname: Yilmaz
authors.forename: Ali I
authors.initials: AI
authors.lastname: Tasci
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000473:pathology / Q000601:surgery; D000368:Aged; D015331:Cohort Studies; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000235:genetics; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D012333:RNA, Messenger / Q000097:blood*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: D012333:RNA, Messenger; D017430:Prostate-Specific Antigen